May 2026 - Complement Factor D Inhibitors drug patent information, global generic entry, market access

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alexion Pharms Inc	VOYDEYA	danicopan	TABLET;ORAL	218037-002	Mar 29, 2024		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Alexion Pharms Inc	VOYDEYA	danicopan	TABLET;ORAL	218037-002	Mar 29, 2024		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Alexion Pharms Inc	VOYDEYA	danicopan	TABLET;ORAL	218037-002	Mar 29, 2024		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Alexion Pharms Inc	VOYDEYA	danicopan	TABLET;ORAL	218037-001	Mar 29, 2024		RX	Yes	No	⤷ Start Trial	⤷ Start Trial		Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: May 18, 2026

Complement Factor D inhibitors target the alternative pathway of complement activation by blocking Factor D (CFD), positioning these assets as competitive immunology drugs for complement-mediated diseases. The patent landscape concentrates around (1) small-molecule CFD inhibitors, (2) antibody or biologic approaches to complement components upstream/downstream of CFD, and (3) formulation and method-of-treatment IP. Commercially, market outcomes depend on payer alignment to target populations, safety and infection-risk management, and differentiation versus terminal-pathway inhibitors (C5) that already have clinical and market validation.

What drugs are complement Factor D inhibitors and how do they work?

Answer: Complement Factor D inhibitors block CFD, a serine protease that is essential for alternative-pathway C3 convertase formation (C3bBb). This reduces generation of C3 split products and downstream amplification, aiming to control complement-driven inflammation without directly blocking terminal complement complex formation (C5b-9).

Key mechanism-of-action mapping to competitive positioning

Alternative-pathway control (Factor D): reduces upstream amplification.
Versus C5 inhibitors (terminal blockade): broader downstream suppression but with established efficacy and safety profiles in multiple indications.
Versus C3 inhibitors: more proximal than C5, often with broader complement impact and different safety/payer considerations.

Representative CFD inhibitor modalities (class-level)

Small molecules: Typical for CFD given enzyme target characteristics.
Biologics/large molecules: Less common for CFD specifically, more common for complement targets that are tractable to antibody formats (C5, C3, etc.).

Which complement Factor D inhibitors have the strongest patent estate?

Answer: The strongest CFD-specific patent estates track to the earliest filing strategies for small-molecule CFD inhibitors and their follow-on patent families covering polymorphs, salt forms, crystallization processes, sustained-release or patient-compliance formulations, and method-of-use for defined complement-mediated diseases.

How to evaluate “strength” in CFD IP portfolios

For CFD inhibitors, the commercially relevant strength factors usually include:

Breadth of claims across:
- compound structure coverage (core scaffold + analogs)
- stereochemistry/tautomer/polymorph details
- salt and solvates
Duration via:
- priority chain management
- layering of intermediate patents through follow-on filings
Regulatory tie-in via:
- listing for the approved drug in the Orange Book (when applicable)
- method-of-use or formulation patents that can block generic entry

What patents protect complement Factor D inhibitors (compound, formulation, and method-of-use)?

Answer: Patent protection for CFD inhibitors usually splits into three layers: core compound claims, solid-state/formulation claims, and therapeutic method-of-use claims for specific diseases and patient cohorts.

Compound patents: what they usually cover

Core chemical entity and close analogs
Key binding motifs for CFD inhibition (structure-activity relationship coverage)
Enantiomers or defined stereochemical configurations when relevant
Salt forms

Formulation patents: what they usually cover

Tablet/capsule compositions
Controlled release matrices and coating systems
Solvates and polymorph-specific formulations
Manufacturing process patents that support IP separation from generic manufacturing

Method-of-use patents: what they usually cover

Indication-specific dosing regimens
Biomarker-defined subgroups
Combination therapies (CFD inhibitor plus another immunomodulator or complement-pathway agent)

Portfolio mapping framework used in CFD licensing and litigation

Primary expiry: earliest compound patent term
Secondary expiry: formulation/polymorph patents (often 1-5 years later)
Late-stage blockers: method-of-use patents tied to approved label scope and potentially Orange Book status

When do complement Factor D inhibitor patents expire and when does exclusivity end?

Answer: The effective exclusivity timeline typically spans two parallel tracks:

Patent term for the latest enforceable compound/formulation/method-of-use patent.
Regulatory exclusivity (new chemical entity, new molecular entity, and pediatric extensions where applicable), which can extend brand protection even after the core patent expires, depending on Orange Book listings and NDA/BLA status.

What typically drives the “last-to-expire” date in CFD programs

Follow-on filings on:
- crystalline forms
- improved processes and yield
- dosing formulations (e.g., tablet strengths or controlled release)
Label expansions that support new method-of-use patents

How CFD differs from C5 inhibitor timelines

CFD programs often compete with:

faster payer adoption of terminal-pathway inhibitors,
older patent estates in C5 space,
and entrenched clinical endpoints and safety data. This makes later-stage IP layering more important for CFD differentiation.

Which patents support Paragraph IV generic challenges for complement Factor D inhibitors?

Answer: For small-molecule CFD inhibitors approved as NDAs, Paragraph IV certifications typically target the latest listed Orange Book patents, often formulation and method-of-use patents if compound patents are older.

What generics usually certify against

Formulation patents listed for the marketed strength/dosage form
Method-of-use patents listed for label-specific dosing or patient selection
Process patents when directly tied to manufactured intermediates or finished product

Settlement dynamics that drive market timing

Generic settlement patterns in complement inhibitor classes usually follow:

30-month stay triggered by PIV filing,
settlement with “no-launch” dates tied to patent expiry or carve-outs for non-infringing products,
authorized generic arrangements in some cases.

What is the Orange Book status of complement Factor D inhibitors?

Answer: Orange Book protection for CFD inhibitors is evaluated through patent listing type (drug substance, drug product, method-of-use) and the latest expiration dates for each listing.

Orange Book checklist used for launch-risk scoring

Listed patent numbers and expiration dates
Patent type distribution (drug substance vs drug product vs method-of-use)
Whether method-of-use patents align tightly to the approved label (higher enforcement likelihood)
Whether multiple NDA holders or label variations exist (strength-dependent risk)

How does the patent estate for complement Factor D inhibitors compare with C5 and C3 inhibitors?

Answer: CFD inhibitor patents tend to be newer than many C5 inhibitor estates, but may have narrower initial molecule-specific claims. C5/C3 portfolios often have long-standing method-of-use and combination layering across multiple indications, creating a high-density enforcement environment. CFD programs compensate through targeted follow-on filings and label-driven method-of-use claims.

Practical comparison drivers for investors and licensors

Claim density: number of enforceable listings near “last-to-expire”
Indication breadth: whether the CFD inhibitor has multiple protected indications or only a narrow label
Cross-licensing risk: complement families often spawn extensive continuation filings; freedom-to-operate depends on core chemical scaffolds and formulation IP

What patent litigation affects complement Factor D inhibitors?

Answer: CFD litigation risk mirrors typical small-molecule biologic-adjacent immunology patterns: compound and formulation/method-of-use enforcement, PIV challenges for generics, and infringement disputes focused on claim construction and label-anchored dosing.

Litigation issue types observed in complement inhibitor disputes

infringement based on:
- structure equivalence (core scaffold coverage),
- formulation composition (excipients, release profile),
- process similarity (manufacturing steps).
validity attacks based on:
- obviousness using prior art complement protease inhibitors,
- enablement or written description,
- lack of novelty over earlier scaffolds.

What generic entry risks exist for complement Factor D inhibitors?

Answer: Generic entry risk depends on whether the CFD inhibitor is protected primarily by:

early-expiring compound patents (higher generic likelihood once they expire), or
later-expiring formulation and method-of-use patents listed in the Orange Book (higher risk of delayed generic entry).

Entry risk scoring dimensions

Latest Orange Book patent expiration date
Number of listed patents that are “market-blocking” (method-of-use and drug product)
Strength of non-infringement levers:
- alternate polymorph or salt
- alternate dosage forms outside the listed strengths
- different dosing regimen (if method-of-use claims are regimen-specific)

Do biosimilars apply to complement Factor D inhibitors?

Answer: Biosimilars apply if the CFD inhibitor is a biologic (BLA pathway). Most CFD inhibitors in practice are small molecules, making biosimilar pathways less directly relevant. Where biologics targeting complement are involved, biosimilar risk is governed by BLA-specific exclusivity, manufacturing comparability, and interchangeability questions.

Practical rule for complement factor D specifically

If the product is a small molecule NDA: no biosimilar regime.
If a biologic CFD-adjacent complement inhibitor exists under BLA: evaluate biosimilar exclusivity and patent estate under BPCIA.

What formulations are protected by complement Factor D inhibitor patents?

Answer: Protected formulations usually include specific solid-state forms and dosage forms used in marketed products, plus controlled-release variants if they exist in the development program.

Formulation IP hotspots

polymorph-specific claims,
salt/solvate claims,
crystallization process claims,
tablet/capsule composition claims tied to the marketed strength.

How formulation IP blocks generic substitution

generics must match:
- active ingredient identity (including polymorph/salt if claimed),
- dissolution profile if formulation claims exist,
- and dosing regimen if method-of-use claims exist.

What method-of-use patents protect complement Factor D inhibitors?

Answer: Method-of-use patents typically protect:

treatment of complement-mediated diseases using CFD inhibition,
dosing regimens,
and selected biomarker-defined populations.

Method-of-use claim types seen in complement

“A method of treating [indication] in a patient with [biomarker].”
“A method comprising administering [dose] of [compound] at [interval].”
“A method using CFD inhibition in combination with [other therapy].”

Enforcement leverage

Method-of-use patents are high leverage when:

the label tracks the claim elements closely,
the dosing regimen is fixed or strongly preferred,
biomarkers are embedded in prescribing language.

Which companies are active in complement Factor D inhibitors and patent filings?

Answer: The CFD landscape is concentrated among complement-focused pharma companies. Competitive intensity depends on:

clinical readouts across complement-mediated indications,
pace of label expansion,
and the density of follow-on patent filings that sustain exclusivity.

Competitive landscape logic used in diligence

map each competitor’s CFD IP families:
- earliest priority date,
- key follow-on categories (formulation, method-of-use),
- jurisdiction coverage.
map each competitor’s regulatory milestone dates to “when the label will narrow or expand.”

What licensing deals and partnership structures shape the CFD market?

Answer: CFD inhibitors often rely on licensing models that split:

worldwide development and commercialization rights,
co-development on clinical programs,
and regional manufacturing rights.

Typical deal terms affecting exclusivity value

field-of-use restrictions,
sublicensing rights,
step-in rights in litigation,
milestone-based payments that correlate with regulatory approvals and label scope.

Where are complement Factor D inhibitors protected geographically?

Answer: Geographic coverage typically concentrates in:

US (Orange Book enforcement for NDAs),
EU (EP and national validations),
UK and select major jurisdictions (CN, JP, KR) for global revenue protection and litigation leverage.

Jurisdictional differences that matter for CFD enforcement

US: Orange Book patent listing and PIV pathways for generics
EU: EP validity challenges and national injunction outcomes
UK: post-Brexit enforcement architecture for EP-derived rights

How do complement Factor D inhibitor market dynamics depend on safety and infection risk management?

Answer: Complement pathway inhibition alters host defense. Market adoption hinges on:

infection monitoring protocols,
prophylaxis and vaccination approaches where recommended,
and payer confidence in long-term safety for chronic treatment regimens.

Commercial impact levers for CFD inhibitors

clinician comfort with complement inhibition,
inpatient vs outpatient administration preferences,
rebate dynamics and formulary access driven by total cost of therapy.

Key patent-and-market timing blueprint for complement Factor D inhibitors

Answer: The launch and licensing forecast for CFD inhibitors depends on aligning three dates:

Primary compound patent expiry
Latest formulation/method-of-use patent expiry (Orange Book “last listed”)
Regulatory exclusivity end (NCE/NME and pediatric extensions if any)

Launch forecast structure used in investment models

Generic launch feasible if:
- no enforceable, listed patents block market entry,
- and settlement does not impose a no-launch date.
Brand risk increases when:
- Orange Book listings thin out near expiry,
- PIV filings target late-stage method-of-use patents (suggesting generic intent to wait until those are resolved).

Key Takeaways

Complement Factor D inhibitors are positioned as alternative-pathway complement control agents with differentiation potential versus established C5 inhibitors.
The patent estate for CFD inhibitors typically stacks compound, formulation (polymorph/salt/crystal/process), and method-of-use claims tied to label-specific dosing and indication scope.
Generic entry risk is driven by the latest Orange Book-listed patents, often drug product and method-of-use rather than the earliest compound patents.
Market success depends as much on payer and clinician adoption dynamics (safety management, infection-risk protocols, chronic use practicality) as on efficacy differentiation.

FAQs

1) What makes Factor D inhibition different from C5 inhibition in clinical and commercial terms?
Factor D inhibition targets the alternative-pathway amplification step, while C5 inhibition blocks terminal complement complex formation; this affects risk management frameworks and payer comfort with long-term outcomes.

2) What patent types most commonly block generic entry for small-molecule complement inhibitors?
Method-of-use and drug product (formulation) patents listed in the Orange Book often block entry even when early compound patents expire.

3) How do polymorph and salt patents affect generic product development for complement inhibitors?
They can force generics to match or design around specific solid forms; if such forms are claimed, they create non-infringement and approval-comparability complexity.

4) Does the patent strategy for complement inhibitors vary by indication expansion?
Yes. New indications can support new method-of-use filings and label-anchored patent listings that extend enforcement leverage.

5) What litigation timeline typically follows a Paragraph IV filing for complement inhibitor NDAs?
A PIV triggers FDA 30-month stay while district court litigation proceeds, with potential settlements that define no-launch or authorized-generic terms tied to patent expiry.

References (APA)

FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
FDA. (n.d.). Small Business and the Orange Book. U.S. Food and Drug Administration.
U.S. Code. (n.d.). Title 21, Chapter 9, Subchapter IV: Drugs and New Drugs (including Hatch-Waxman provisions). Legal Information Institute, Cornell Law School.
U.S. Code. (n.d.). Title 35: Patents (patent term and enforcement framework). Legal Information Institute, Cornell Law School.